Company | Type Of | Number Of | Amount | Investors; Placement Agents; |
(Symbol) | Financing | Shares, Units | Raised (M) | Details (Date) |
Or Warrants (M) | ||||
Aastrom Biosciences | Private | ND | $5 | Aastrom sold $5M in Series I convertible |
Inc. (ASTM) | placement | preferred stock to a single investor; the pre- | ||
ferred stock yields 5% annual interest and is | ||||
convertible for the 1st nine months only af- | ||||
ter the market price of Aastrom's common | ||||
stock reaches $4.83 per share; Aastrom will | ||||
register the underlying shares for resale (7/6) | ||||
Advanced Tissue | Private | ND | $25 | Advanced Tissue raised $25M through the |
Sciences Inc. (ATIS) | placement | sale of Series B convertible preferred | ||
stock to a group of new investors; the pre- | ||||
ferred stock, which earns 5% interest per year, | ||||
can be converted into common stock at a | ||||
premium to market if the trading price goes | ||||
above $8 per share; Advanced Tissue will | ||||
register the underlying shares for resale | ||||
(7/13) | ||||
Amylin | Institutional | 4S | $13 | Amylin sold 4M shares of newly issued |
Pharmaceuticals | offering of | stock at $3.25 each to 2 new institutional | ||
Inc. (AMLN) | registered | investors and to company insiders, inclu- | ||
stock | ding Joseph Cook Jr., chairman and CEO, | |||
and Howard (Ted) Greene, cofounder and | ||||
director; also investing were the State of | ||||
Wisconsin Investment Board, a current | ||||
institutional investor and certain other | ||||
individual investors; Hambrecht & Quist | ||||
LLC acted as advisor (7/29) | ||||
ChemTrak Inc. | Private | ND | $0.2 | ChemTrak said it received $150,000 of |
(CMTRD) | placement | equity financing, but supplied no details | ||
(7/9) | ||||
Corvas | Exercise of | 1.03S | $3.7 | Corvas received $3.7M from a group of |
International | warrants | current institutional investors that accepted | ||
Inc. (CVAS) | the firm's offer to exercise their warrants | |||
early at a discount; Corvas will issue 1.03M | ||||
shares in exchange (7/22) | ||||
Hemosol Inc. | Rights | 2.44U | $5 | Hemosol sold 2.44M units at US$2.05 each |
(TSE:HML; Canada) | offering | to existing shareholders; each unit consists | ||
of 1 common share and 0.5 warrant that can | ||||
be used to buy 1 share at US$2.57 until | ||||
12/21/99; major shareholder MDS Inc. sub- | ||||
scribed to 1.46M of the units, increasing | ||||
its stake in Hemosol to 34% (7/24) | ||||
LeukoSite Inc. | Private | 1.97S | $11.8 | LeukoSite sold 1.97M unregistered shares |
(LKST) | placement | to new and current shareholders at $6 each | ||
(an 18.6% discount to the market) for pro- | ||||
ceeds of $11.8M; new investors included Gold- | ||||
man, Sachs & Co. and Perseus Capital LLC (7/6) | ||||
Pacific | Private | 1.47S | $2.6 | Pacific Pharmaceuticals and its subsidiary |
Pharmaceuticals | placement | B-G Development Corp. raised $2.6M by | ||
Inc. (PHA) | selling 1.47M convertible preferred shares | |||
of B-G Development to undisclosed invest- | ||||
ors; each share of preferred stock is con- | ||||
vertible into 1 share common stock (7/8) | ||||
Ribi ImmunoChem | Private | 0.082S | $8.2 | Ribi raised $8.24M by selling 8,240 shares |
Research Inc. (RIBI) | placement | of convertible preferred stock at $1,000 each | ||
to a single institutional investor; the preferred | ||||
stock pays 5% annual interest and can be | ||||
converted into common stock after 90 days | ||||
but before 120 days at $6.04 per share; there- | ||||
after, the conversion rate is a floating price; | ||||
Ribi will register the underlying stock for | ||||
resale (7/17) | ||||
SciClone | Equity line | — | $32 | SciClone will get a $32M line of credit from |
Pharmaceuticals | of credit | an institutional investor; the fund is managed | ||
Inc. (SCLN) | by the Palladin Group LP; SciClone can access | |||
up to $32M over a 2-year period (up to $4M | ||||
per quarter) through the sale of its common | ||||
stock, at a 3% discount to market; the investor | ||||
received a 5-year warrant to buy 0.2M shares | ||||
of SciClone stock at $5.53 per share (7/8) | ||||
Therapeutic | Interim | ND | $3.2 | Therapeutic Antibodies raised $3.15M in |
Antibodies Inc. | financing | interim financing, which consisted of | ||
(LSE:TAB) | short-term interest-bearing notes with | |||
warrants; the notes carry a 15% coupon and | ||||
are repayable in 180 days; the 5-year war- | ||||
rants can be used to buy 0.315M shares of | ||||
common stock at market price; the com- | ||||
pany's chairman, Martin Brown, and its | ||||
CEO, Andrew Heath, both participated in the | ||||
financing, contributing $0.375M in all (6/29)* | ||||
Tm Bioscience Corp. | Private | 18.47W | $10.1 | Tm Bioscience sold 18.47M special war- |
(Canada) | placement | rants at US$0.55 each to 2 main investors; | ||
13.1M of the warrants were placed privately | ||||
by Yorkton Securities Inc.; the remainder | ||||
were bought by the Canadian Medical Dis- | ||||
coveries Fund; Tm Biosciences will regis- | ||||
ter the underlying shares for resale; each | ||||
warrant can be converted into 1 common | ||||
share and 0.5 common share purchase | ||||
warrant; each common share purchase war- | ||||
rant can be exercised at US$0.68 until | ||||
6/24/00; prices converted at a rate of | ||||
C$1.47/US$1 (6/24)* | ||||
Vion | Private | ND | $5 | Vion placed $5M in convertible preferred |
Pharmaceuticals | placement | stock with existing investors Elliott Assoc- | ||
Inc. (VION) | iates LP and Westgate International LP (7/1) | |||
TOTAL: $111.5M | ||||
NOTES: | ||||
* Those financings marked with an asterisk (Therapeutic Antibodies Inc. and Tm Biosciences Corp.) occurred in 6/98. The proceeds have been attributed to that month and are not included in the totals above. | ||||
LSE = London Stock Exchange; ND = Not disclosed, reported and/or available; S = Shares; U = Units; TSE = Toronto Stock Exchange; W = Warrants | ||||
The financings in this chart include loans, bridge financings and other interim measures as well as sale of business units, debt offerings, rights offerings, exercise of warrants, institutional offerings of registered stock and standard private placements. |